Search - tctmd.com

Displaying 481 - 500 of 1574

Sort: Relevancy | Date

Presentation TCT 2021

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

Presenter: Pieter Smits

November 05, 2021

Presentation TCT 2021

PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation

Presenter: Pavel Osmancik

November 05, 2021

Presentation TCT 2021

AMULET IDE: One-Year Device Closure From a Randomized Trial of Amulet Versus Watchman for Left Atrial Appendage Occlusion

Presenter: Dhanunjaya Lakkireddy

November 05, 2021

Presentation TCT 2021

CHOICE-CLOSURE: A Randomized Trial of Plug-Based Versus Suture-Based Large-Bore Vascular Closure

Presenter: Mohamed Abdel-Wahab

November 05, 2021

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

Presentation TCT 2021

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Presenter: David Cohen

November 05, 2021

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

Presentation TCT 2021

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presenter: Nicolas Van Mieghem

November 05, 2021

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Todd Neale

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Presenter: Ori Ben-Yehuda

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Presenter: Joanna Chikwe

November 05, 2021

Presentation TCT 2021

FFR REACT: A Randomized Trial of FFR-Guided PCI Optimization by IVUS Versus No Optimization

Presenter: Joost Daemen

November 05, 2021

Presentation TCT 2021

The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Clinical Trials Status Update

Presenter: David E. Kandzari

November 04, 2021

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

Presentation TCT 2021

Triluminate Registry: Lessons Learned for TEER Trial Design

Presenter: Georg Nickenig

November 04, 2021

Presentation TCT 2021

Pragmatic Clinical Trials: The Future is Now?

Presenter: Sreekanth Vemulapalli

November 04, 2021

News Conference News TCT 2021

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

Caitlin E. Cox

November 04, 2021

Presentation TCT 2021

iFR-SWEDEHEART: Five-Year Outcomes of a Randomized Trial of iFR-Guided vs. FFR-Guided PCI

Presenter: Matthias Götberg

November 04, 2021

Presentation TCT 2021

Adapting Clinical Trials to a Black Swan Event, from Industry Perspective

Presenter: Sandeep Brar

November 04, 2021

Presentation TCT 2021

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

Presenter: Ajay Kirtane

November 04, 2021

Advertisement

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation

AMULET IDE: One-Year Device Closure From a Randomized Trial of Amulet Versus Watchman for Left Atrial Appendage Occlusion

CHOICE-CLOSURE: A Randomized Trial of Plug-Based Versus Suture-Based Large-Bore Vascular Closure

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

FFR REACT: A Randomized Trial of FFR-Guided PCI Optimization by IVUS Versus No Optimization

The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Clinical Trials Status Update

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Triluminate Registry: Lessons Learned for TEER Trial Design

Pragmatic Clinical Trials: The Future is Now?

iFR Matches FFR Through 5 Years: iFR-SWEDEHEART

iFR-SWEDEHEART: Five-Year Outcomes of a Randomized Trial of iFR-Guided vs. FFR-Guided PCI

Adapting Clinical Trials to a Black Swan Event, from Industry Perspective

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content